Psoriasis - Causes and Pathogenesis

Understanding Psoriasis: Etiology, Risk Factors, and Pathophysiology Introduction Psoriasis is a complex inflammatory skin disease that arises from both genetic predisposition and environmental triggers. Understanding why psoriasis develops requires examining two complementary perspectives: what makes certain individuals susceptible to the disease, and what biological mechanisms cause the characteristic skin changes. This knowledge is essential for recognizing risk factors, predicting disease course, and understanding how modern treatments work. Genetic Predisposition Family History and Hereditary Risk Psoriasis shows significant hereditary clustering. Approximately one-third of patients report a family history of the condition, indicating that genetic factors play an important role in disease susceptibility. The strongest evidence for genetic influence comes from identical twin studies, which show a 70% concordance rate—meaning if one identical twin has psoriasis, the other has a 70% chance of developing it as well. This high concordance rate is remarkable because identical twins share 100% of their DNA, yet the rate isn't 100%, which tells us that environmental factors also matter. Major Susceptibility Genes The primary genetic risk factor is a region called PSORS1 (psoriasis susceptibility locus 1) located on chromosome 6. This single locus accounts for 35–50% of the inherited genetic risk for psoriasis. While PSORS1 is the major player, other genes also contribute to disease susceptibility, which explains why not all genetically predisposed individuals develop psoriasis—multiple genetic and environmental factors must align. Environmental and Lifestyle Triggers Even individuals with strong genetic predisposition may never develop psoriasis unless exposed to triggering factors. Environmental triggers are thought to activate the dormant genetic susceptibility. Understanding these triggers is clinically important because patients can often modify their environment or behavior to prevent flares. Skin Trauma and Infections Skin injury represents one of the most common triggers. Trauma such as scratching, burns, surgery, or any significant skin damage can precipitate psoriasis development at the site of injury (a phenomenon called the Köbner phenomenon). Among infections, streptococcal throat infections deserve special attention. They commonly precede guttate psoriasis, particularly in children and adolescents. Guttate psoriasis is a distinct clinical form characterized by numerous small, drop-like lesions that often appear acutely after a streptococcal infection. Medications and Corticosteroid Withdrawal Certain medications can trigger or worsen psoriasis. Notably, abrupt withdrawal of topical corticosteroids can cause a rebound flare—a sudden, often severe exacerbation of disease. This rebound effect is clinically important when tapering these medications; they should be discontinued gradually rather than abruptly. Lifestyle and Systemic Factors Multiple lifestyle factors exacerbate psoriasis: Psychological stress is consistently reported as a trigger Winter season commonly worsens disease, likely due to reduced sunlight exposure and increased skin dryness Hot water exposure and excessive washing can damage the skin barrier and trigger flares Scratching perpetuates the Köbner phenomenon Skin dryness impairs the protective barrier function Alcohol consumption and cigarette smoking both worsen disease, with smoking being a particularly strong risk factor Obesity is associated with increased disease severity These factors are interconnected; for example, stress may lead to increased scratching, which in turn triggers new lesions through the Köbner phenomenon. Pathophysiology: How Psoriasis Develops Psoriasis pathophysiology involves a coordinated abnormality of both the immune system and the skin. Understanding this two-part process explains both why treatments target immune pathways and why the disease manifests in the skin. Normal Skin Cell Turnover To appreciate what goes wrong in psoriasis, it's helpful to know normal skin dynamics. Under normal conditions, epidermal keratinocytes (the primary cell type in the outer skin layer) complete their life cycle in approximately 28–30 days. This means it takes about a month for new cells to be born at the base of the epidermis, migrate to the surface, and shed. Accelerated Cell Turnover in Psoriasis In psoriasis, keratinocytes complete their life cycle in only 3–5 days instead of 28–30 days. This dramatic acceleration is approximately 6–10 times faster than normal. This explains the hallmark clinical finding of psoriasis: a buildup of skin cells creating thick, scaly plaques. The rapid turnover doesn't allow proper maturation of skin cells, resulting in an immature, dysfunctional skin barrier. The Immune Cascade Psoriasis is fundamentally an immune-driven disease. The process typically begins with an initiating trigger (skin injury, infection, medication, or stress) that activates immune cells in the dermis (the deeper skin layer beneath the epidermis). Initiation Phase: When skin is damaged or exposed to pathogens, dendritic cells and macrophages recognize the threat and become activated. These professional antigen-presenting cells process and present antigens to T-cells, teaching the adaptive immune system to recognize a threat. Amplification Phase: Activated dendritic cells release interferon-alpha, which promotes differentiation of naive T-cells into two pathogenic types: Th1 cells (T-helper 1 cells) Th17 cells (T-helper 17 cells) The Th17 pathway is particularly important in psoriasis pathogenesis. Th17 cells secrete two key inflammatory cytokines: Interleukin-17 (IL-17) Interleukin-22 (IL-22) These cytokines directly stimulate keratinocytes to proliferate rapidly and to release neutrophil-attracting cytokines, recruiting additional immune cells to the lesion. Cytokine Storm: The psoriatic lesion becomes flooded with pro-inflammatory cytokines that perpetuate inflammation: Tumor necrosis factor-alpha (TNF-α) Interleukin-1 beta (IL-1β) Interleukin-6 (IL-6) Interleukin-22 (IL-22) Interleukin-36 gamma (IL-36γ) These cytokines create a self-amplifying cycle: they stimulate keratinocyte proliferation while simultaneously promoting immune cell recruitment, which further amplifies cytokine production. Genetic Influence on Immune Pathways Genetic factors directly shape which immune pathways become dysregulated. Mutations in genes linked to PSORS1 and in the IL12B/IL23R genes amplify inflammatory signaling. Specifically, these genetic variants make the IL-17 and IL-23 pathways more active, lowering the threshold at which immune activation occurs. This explains why genetic predisposition and immune activation are inseparable in psoriasis pathogenesis. Integration: Why Understanding This Matters The three-part model of psoriasis—genetic predisposition, environmental triggers, and immune-mediated pathophysiology—explains both how the disease develops and why treatments work: Genetic predisposition explains why some people are susceptible and others are not Environmental triggers explain why genetically susceptible individuals may develop the disease only under certain conditions Understanding immune pathways (especially IL-17 and IL-23) explains why modern biologic therapies that target these pathways are so effective A patient might carry PSORS1 mutations but remain healthy throughout life if never exposed to significant triggers. Conversely, a streptococcal infection in a genetically susceptible adolescent might activate Th17 cells, triggering the immune cascade that causes guttate psoriasis. <extrainfo> Emerging Research Directions New Biologic Targets Research is rapidly evolving toward more selective immune targeting. Newer agents focus specifically on the Th17/IL-23 axis, particularly interleukin-23p19 inhibitors, which selectively block the specific IL-23 pathway implicated in psoriasis while theoretically preserving beneficial immune responses and host defense mechanisms. Oral Small-Molecule Therapies Complementing traditional biologic therapies (which require injection or infusion), researchers are developing oral small-molecule drugs that work through different immune mechanisms, including Janus kinase inhibitors, protein kinase C inhibitors, mitogen-activated protein kinase inhibitors, and phosphodiesterase-4 inhibitors. Several of these have shown efficacy in phase 2/3 clinical trials, though they may carry immunosuppression-related side effects that require further study. </extrainfo>